NCT03004209

Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Seoul National University Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates the efficacy of erythropoietin in refractory autoimmune encephalitis. Ten patients will receive 100 IU/kg of erythropoietin 3 times a week for 12 weeks.

Detailed description

Erythropoietin can improve the refractory autoimmune encephalitis. Erythropoietin has tissue-protective effect via activation of Janus kinase (JAK)-2, signal transducer and activator of transcription (STAT)-5 pathway and NF-kappa B pathway. The activation of JAK-2 and STAT-5 promote hemoglobin synthesis and facilitate cell cycle progression. Also, NF-kappa B pathway inhibition regulates pro-inflammatory cytokine production. We expect that erythropoietin may lead to improve the symptoms and outcome of autoimmune encephalitis.

Conditions

• Autoimmune Encephalitis

Interventions

Type	Name	Description
DRUG	Erythropoietin	three times per a week 100IU / k

Timeline

• Start date: 2016-12-01
• Primary completion: 2018-02-06
• Completion: 2018-02-06
• First posted: 2016-12-28
• Last updated: 2021-09-29

Locations

1 site across 1 country: South Korea